130 related articles for article (PubMed ID: 19807550)
1. Management and costs of severe psoriasis: the role of new biologics.
Feldman SR; Pearce DJ
Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
4. Outcomes associated with the use of biologic agents in moderate to severe psoriasis.
Price J; Bhosle M; Feldman SR; Balkrishnan R
J Drugs Dermatol; 2007 Mar; 6(3):259-67. PubMed ID: 17373187
[TBL] [Abstract][Full Text] [Related]
5. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
Tzu J; Kerdel F
Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
[TBL] [Abstract][Full Text] [Related]
6. Disease and treatment burden of psoriasis: examining the impact of biologics.
Raval K; Lofland JH; Waters H; Piech CT
J Drugs Dermatol; 2011 Feb; 10(2):189-96. PubMed ID: 21283925
[TBL] [Abstract][Full Text] [Related]
7. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
[TBL] [Abstract][Full Text] [Related]
8. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
9. Care of patients with psoriasis: an audit of U.K. services in secondary care.
Eedy DJ; Griffiths CE; Chalmers RJ; Ormerod AD; Smith CH; Barker JN; Potter J; Ingham J; Lowe D; Burge S
Br J Dermatol; 2009 Mar; 160(3):557-64. PubMed ID: 19120330
[TBL] [Abstract][Full Text] [Related]
10. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry.
Nast A; Reytan N; Rosumeck S; Erdmann R; Rzany B
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1337-42. PubMed ID: 18624864
[TBL] [Abstract][Full Text] [Related]
11. Do utilization management controls for phototherapy increase the prescription of biologics?
Simpson GL; Yelverton CB; Rittenberg S; Feldman SR
J Dermatolog Treat; 2006; 17(6):359-61. PubMed ID: 17853310
[TBL] [Abstract][Full Text] [Related]
12. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis.
Yelverton CB; Kulkarni AS; Balkrishnan R; Feldman SR
Manag Care Interface; 2006 Jan; 19(1):33-6, 39. PubMed ID: 16453993
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists.
Patel V; Horn EJ; Lobosco SJ; Fox KM; Stevens SR; Lebwohl M
J Am Acad Dermatol; 2008 Jun; 58(6):964-9. PubMed ID: 18378352
[TBL] [Abstract][Full Text] [Related]
15. Phototherapy, psoriasis, and the age of biologics.
Richard EG; Hönigsmann H
Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
[TBL] [Abstract][Full Text] [Related]
16. Decision points for the initiation of systemic treatment for psoriasis.
Feldman SR; Koo JY; Menter A; Bagel J
J Am Acad Dermatol; 2005 Jul; 53(1):101-7. PubMed ID: 15965429
[TBL] [Abstract][Full Text] [Related]
17. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasis.
Scheinfeld N; Parish D
Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):545-57. PubMed ID: 20528318
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
